The Federal Court of Appeal upheld the validity of Canadian Patent 2,436,668 which covers Form I ODV succinate (marketed as PRISTIQ) in two separate appeals by Apotex Inc. and Teva Canada Ltd, finding that the claims were novel and inventive.
Norton Rose Fulbright Canada LLP